Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Modakafusp alfa first-in-human study in relapsed/refractory multiple myeloma
MOH_2022-10-13_012123Phase 2Not yet recruiting
- Sponsor
- Takeda
- Start
- Sep 2022
- Modality
- Immunomodulatory ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of modakafusp alfa in multiple myeloma (MM) (2 arms), sponsored by Takeda. Primary endpoints: Safety and tolerability, Anti-myeloma activity and 1 more. Planned start Sep 2022; status: not yet recruiting.
02
Drugs
modakafusp alfa
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on MOH_2022-10-13_012123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-10-13_012123.